Global Newborn Blood Screening Systems Market Growth (Status and Outlook) 2025-2031

The global Newborn Blood Screening Systems market size is predicted to grow from US$ 691 million in 2025 to US$ 1083 million in 2031; it is expected to grow at a CAGR of 7.8% from 2025 to 2031.

Newborn blood screening systems, also known as newborn screening (NBS), are public health programs designed to identify certain disorders in newborn babies shortly after birth. These systems involve taking a few drops of blood from a babys heel, usually within the first 24 to 48 hours after birth, and testing it for a variety of genetic, metabolic, and developmental conditions.



The tests conducted through newborn blood screening systems can vary based on location, but they often include screenings for disorders such as phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis, sickle cell disease, and many others. Early detection of these conditions allows for early intervention and treatment, which can significantly improve the babys health outcomes and quality of life.



Newborn blood screening is typically mandatory or strongly recommended in many countries as part of standard newborn care. Its an essential preventive measure aimed at early identification of potential health issues, enabling timely medical interventions that can prevent or minimize the impact of certain conditions on a childs development.



Newborn blood screening systems include screening kits, consumables, instruments and software.

Market Drivers: Rising Prevalence of Disorders: The increasing incidence of genetic, metabolic, and congenital disorders among newborns drives the demand for comprehensive screening systems.

Government Initiatives: Government-led programs mandating newborn screening in many countries promote the adoption of screening systems, ensuring early detection and intervention for better health outcomes.

Rising Healthcare Expenditure: Increased healthcare spending, especially in developing regions, allows for better infrastructure and accessibility to screening systems and services.

Market Restrictions: Cost Constraints: High initial setup costs for screening equipment and ongoing operational expenses can limit the implementation of comprehensive newborn screening programs in certain regions or healthcare settings.

Limited Access to Advanced Technology: Some regions, especially in low-resource settings, may lack access to sophisticated screening technologies, hindering comprehensive screening programs.

Variability in Healthcare Policies: Differences in healthcare policies and regulations across regions can affect the standardization and uniformity of newborn screening programs.

LPI (LP Information)' newest research report, the “Newborn Blood Screening Systems Industry Forecast” looks at past sales and reviews total world Newborn Blood Screening Systems sales in 2024, providing a comprehensive analysis by region and market sector of projected Newborn Blood Screening Systems sales for 2025 through 2031. With Newborn Blood Screening Systems sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Newborn Blood Screening Systems industry.

This Insight Report provides a comprehensive analysis of the global Newborn Blood Screening Systems landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Newborn Blood Screening Systems portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Newborn Blood Screening Systems market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Newborn Blood Screening Systems and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Newborn Blood Screening Systems.

This report presents a comprehensive overview, market shares, and growth opportunities of Newborn Blood Screening Systems market by product type, application, key players and key regions and countries.

Segmentation by Type:
Instrument and Kits
Consumables
Software

Segmentation by Application:
Hospital
Independent Laboratories
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PerkinElmer
Waters Corporation
Danaher
Thermo Fisher
Trivitron Healthcare
Agilent Technologies
Bio-Rad Laboratories
Zivak Technologies

Please note: The report will take approximately 2 business days to prepare and deliver.